Industry perspective: Scale up challenges for cell & gene therapy manufacturers
In an interview hosted by Biotech Week Boston, Dr. Ger Brophy, Avantor's Executive Vice President of Biopharma Production, provided insights into cell and gene therapy industry challenges.
This informative discussion examines new trends in cell and gene therapy manufacturing development, global supply chain issues due to increasing demand and obstacles in the workflow process. Learn steps biomanufacturers can take to mitigate raw material shortages and how to overcome scale up challenges faced by many in the industry.
Hosted by
Dr. Ger Brophy
Executive Vice President, Biopharma Production
Dr. Ger Brophy is our Executive Vice President, Biopharma Production. In his current role, Dr. Brophy is responsible for developing and implementing our Biopharma Production offering to support the current and future needs of our customers. Prior to joining Avantor, Dr. Brophy held a variety of research and development, strategy, advanced systems, and business development positions with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics and Amersham for nearly 30 years. Dr. Brophy earned a Bachelor of Science in biotechnology, as well as a doctorate in molecular biology from Dublin City University in Ireland.